Compare ARE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | IOVA |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.7B |
| IPO Year | 1997 | 2008 |
| Metric | ARE | IOVA |
|---|---|---|
| Price | $43.44 | $14.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $51.93 | $14.40 |
| AVG Volume (30 Days) | 2.0M | ★ 12.5M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.82% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $3,026,556,000.00 | N/A |
| Revenue This Year | N/A | $56.63 |
| Revenue Next Year | N/A | $42.41 |
| P/E Ratio | $25.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.41 | $1.76 |
| 52 Week High | $78.51 | $15.37 |
| Indicator | ARE | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 59.41 |
| Support Level | $41.44 | $3.57 |
| Resistance Level | $55.20 | $15.00 |
| Average True Range (ATR) | 1.64 | 0.92 |
| MACD | -0.07 | -0.17 |
| Stochastic Oscillator | 43.03 | 58.17 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.